ESMO Press Office

The ESMO Press Office welcomes media professionals interested in reporting on cancer.

For enquiries please contact us on:
media@esmo.org

ESMO 2018 640x90 Hashtag

 

ESMO Press Programme : press releases schedule

The following abstracts are included in the ESMO 2018 press programme and will be accompanied by a press release.

Please note that for some them, the publication schedule may differ from the general one posted above.

Upon publication, direct links to the press releases will be added.

FPN Title Author name Embargo lift and press release distribution date/time Press release
1891O_PR Mutational Landscape of Metastatic Cancers Discovered from Prospective Clinical Sequencing at Community Practice Cancer Program R. Alvarez Tuesday, 9 October 2018 at 00:05 CEST Press release
1655P_PR The use of complementary and alternative medicine (CAM) in sarcoma patients K. Sungu-Winkler Wednesday, 10 October 2018 at 00:05 CEST Press release
1632P_PR Characterizing the risk of drug-drug interactions in sarcoma treated patients: role of pharmacist integration A. Bellesoeur Wednesday, 10 October 2018 at 00:05 CEST Press release
360P_PR Breast cancer in Twitter: a real-world data exploratory study R. Sanchez Bayona Friday, 12 October 2018 at 00:05 CEST Press release
1576P_PR Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation? E. Winkler Tuesday, 16 October 2018 at 00:05 CEST Press release
185O_PR Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort B. Pistilli Friday, 19 October 2018 at 00:05 CEST Press release
619PD_PR Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials M. Davidson Friday, 19 October 2018 at 00:05 CEST Press release
1555O_PR Magnitude of Clinical Benefit of Cancer Drugs and Time to Health Technology Assessment (HTA) Decisions in Europe T. Hwang Friday, 19 October 2018 at 10:45 CEST Press release
191PD_PR 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio P. Conte Friday, 19 October 2018 at 16:00 CEST Press release
LBA12_PR PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results C. Hulme Friday, 19 October 2018 at 16:00 CEST Press release
1213P_PR Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV) A. Gobert Saturday, 20 October 2018 at 00:05 CEST Press release
251P_PR Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients J. Martin-Babau Saturday, 20 October 2018 at 00:05 CEST Press release
1777P_PR Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study Q. Tran Saturday, 20 October 2018 at 00:05 CEST Press release
1480P_PR Effects of Physical Exercise in non-operable lung cancer patients undergoing palliative treatment E. Wiskemann Saturday, 20 October 2018 at 00:05 CEST Press release
1684PD_PR Physical Activity (PA) and patterns of Quality of Life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC) A. Di Meglio Saturday, 20 October 2018 at 00:05 CEST Press release
1753P_PR Benefits of Physical Activity and Sport integrated into the care pathway of oncology patient L. Vanlemmens Saturday, 20 October 2018 at 00:05 CEST Press release
1350PD_PR Social and behavioral indicators of undergoing a screening test for lung cancer S. Couraud Saturday, 20 October 2018 at 00:05 CEST Press release
962P_PR Indicators of non-participation in cervical cancer screening: results from the EDIFICE 6 survey T. de La Motte Rouge Saturday, 20 October 2018 at 00:05 CEST Press release
1594P_PR Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey J-F. Morere Saturday, 20 October 2018 at 00:05 CEST Press release
525P_PR Profile of individuals who never undergo colorectal cancer screening J. Viguier Saturday, 20 October 2018 at 00:05 CEST Press release
LBA14_PR The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid F. Perrone Saturday, 20 October 2018 at 15:00 CEST Press release
LBA3_PR Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase III SOLAR-1 trial F. André Saturday, 20 October 2018 at 16:30 CEST Press release
LBA1_PR IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) P. Schmid Saturday, 20 October 2018 at 16:30 CEST Press release
LBA2_PR Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3 M. Cristofanilli Saturday, 20 October 2018 at 16:30 CEST Press release
283O_PR Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer Z. Jiang Saturday, 20 October 2018 at 16:30 CEST Press release
424P_PR Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth? A. Vozy Sunday 21 October 2018 at 00:05 CEST Press release
1682O_PR Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving Fluropyrimidines and/or Irinotecan based therapy A. Sharma Sunday 21 October 2018 at 00:05 CEST Press release
294PD_PR Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program J-S. Frenel Sunday 21 October 2018 at 00:05 CEST Press release
273PD_PR Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients M. Reinisch Sunday 21 October 2018 at 00:05 CEST Press release
293PD_PR Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial C. Zamagni Sunday 21 October 2018 at 00:05 CEST Press release
LBA48_PR CTONG 1103:Erlotinib versus Gemcitabine plus Cisplatin as Neo-adjuvant Treatment for Stage IIIA –N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study W-Z. Zhong Sunday 21 October 2018 at 09:15 CEST Press release
LBA6_PR JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) R. Motzer Sunday 21 October 2018 at 16:30 CEST Press release
LBA5_PR Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476) C. Parker Sunday 21 October 2018 at 16:30 CEST Press release
LBA7_PR Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial K. Moore Sunday 21 October 2018 at 16:30 CEST Press release
LBA18_PR Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) H-J. Lenz Monday, 22 October 2018 at 09:15 CEST Press release
LBA37_PR Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer M. Chalabi Monday, 22 October 2018 at 011:15 CEST Press release
LBA8_PR KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) B. Burtness Monday, 22 October 2018 at 16:30 CEST Press release
LBA9_PR Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy H. Mehanna Monday, 22 October 2018 at 16:30 CEST Press release

See all the ESMO press releases              ESMO on Twitter             

ESMO YouTube Channel ESMO Flickr Stream

Visit our YouTube Channel and get access to our latest videos.

Visit our  Flickr Stream and browse through our entire photo library

ESMO 2017 - Day 1

Policies

Related Links